Pulmonary Embolic Disease: Caval Filtration and Other Stuff. Tony P. Smith, M.D. October 2, 2009



Similar documents
AGENDA. (Nitinol Nickel Titanium Alloy) 7/23/2015

Venous Thromboembolic Treatment Guidelines

Pulmonary Embolism Treatment Update

Position Statement: The Use of VTED Prophylaxis in Foot and Ankle Surgery

Guidelines for diagnosis and management of acute pulmonary embolism

Inconsistencies in the Use of Cardiac Biomarkers or Echocardiography in Patients with Acute Non-Massive Pulmonary Embolism

Thrombosis and Hemostasis

Antithrombotic Therapy for VTE Disease

Antithrombotic Therapy for VTE Disease

Central Venous Catheters and Upper Extremity DVT: Update, Diagnosis and Management

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

ACUTE DVT MANAGEMENT Richard J. DeMasi, MD April 26, 2014

Conserva)ve Treatment of PE/ DVT

Joseph A. Caprini, MD, MS, FACS, RVT

National Guidance and New Protocols

Investor News. Not intended for U.S. and UK media

DVT/PE Management with Rivaroxaban (Xarelto)

To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.

National Guidance and New Protocols

Gruppo di lavoro: Malattie Tromboemboliche

Taole Mokoena DPhil FRCS Department of Surgery University of Pretoria

Guidelines on use of vena cava filters

Venous and Lymphatic Disorders

To define a diagnostic algorithm and treatment strategy for patients with acute pulmonary embolism.

New Oral Anticoagulants. How safe are they outside the trials?

CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014

New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther

Components of CVC Care Bundle. selection

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES

Case III. Disscussion. the UHP ultrasound protocol. Novel Ultrasound Approach to the Empiric Evaluation of the Undifferentiated Hypotensive Patient

Clinical Study Synopsis

To Bridge or Not to Bridge. Periop Anticoagulation Management. Don Weinshenker, MD Ambulatory Care Denver VAMC

1. Utility of transradial approach in endovascular management of chronic mesenteric ischemia

Tunneled Hemodialysis Catheters: Placement and complications

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU

Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital

Resection of Lung Cancer Invading the Mediastinum

Cook Celect and Günther Tulip Vena Cava Filter Patient Guide

INSTEAD at 5-year follow-up shifts the expectations for endovascular treatment

Novel Therapy for Acute Pulmonary Embolism Joe Adams, MD Cardiology Associates of North Mississippi

6/19/2012. Update on Venous Thromboembolism Prophylaxis. Disclosure. Learning Objectives. No conflicts of interest to declare

Trust Guideline for Thromboprophylaxis in Trauma and Orthopaedic Inpatients

XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery

Paul G. Lee. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume III, A. Objective

Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.

Preventing Readmissions

Confirmed Deep Vein Thrombosis (DVT)

DISCLAIMER ARTHROPLASTY SOCIETY VTE INFORMATION

Anticoagulation at the end of life. Rhona Maclean

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

The Fatal Pulmonary Artery Involvement in Behçet s Disease

PARTICULAR ASPECTS OF ANTI-THROMBOTIC TREATMENT IN HIP ARTHROPLASTY

Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012

Thrombophilia. Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Top 10 Thrombosis and Anticoagulation Highlights from ASH 2014

The Role of the Newer Anticoagulants

Atrial Fibrillation An update on diagnosis and management

Surgical Options for Venous Disease. Sandra C Carr MD Vascular Surgery Meriter Wisconsin Heart

ABOUT XARELTO CLINICAL STUDIES

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Published 2011 by the American Academy of Orthopaedic Surgeons 6300 North River Road Rosemont, IL AAOS Clinical Practice Guidelines Unit

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

How do you decide on rate versus rhythm control?

How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto

Fort Hamilton Hospital Specialty: Cardiology Department of Medicine Delineation of Privileges

What Does Pregnancy Have to Do With Blood Clots in a Woman s Legs?

X-Plain Subclavian Inserted Central Catheter (SICC Line) Reference Summary

Clinical Study Synopsis

New Anticoagulants: When and Why Should I Use Them? Disclosures

Results of Surgery in a New Lung Institute in South Texas Focused on the Treatment of Lung Cancer

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

Advanced Heart Failure & Transplantation Fellowship Program

0.9% Sodium Chloride injection may be used in most cases.

PSA Screening for Prostate Cancer Information for Care Providers

UHS CLINICAL CARE COLLABORATION: Outpatient & Inpatient

ABSTRACT The American Physical Therapy Association (APTA), in conjunction with the

September 12, Dear Dr. Corrigan:

Interventional Cardiology Peripheral Interventions Rhythm Management

Tranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies

STROKE PREVENTION IN ATRIAL FIBRILLATION

Duration of Dual Antiplatelet Therapy After Coronary Stenting

A Patient s Guide to Primary and Secondary Prevention of Cardiovascular Disease Using Blood-Thinning (Anticoagulant) Drugs

Prior Authorization Guideline

Antiplatelet and Antithrombotics From clinical trials to guidelines

National Patient Safety Goals Effective January 1, 2015

Transcription:

Pulmonary Embolic Disease: Caval Filtration and Other Stuff Tony P. Smith, M.D. October 2, 2009

Controversies in Treatment of Acute Pulmonary Embolic Disease Scope of the problem Transcatheter therapy Inferior vena caval filters Superior vena caval filters

Pulmonary Embolism scope of the problem 650,000 patients annually in the U.S. Up to 150,000 deaths 15% of all in hospital deaths Where do these numbers come from?

Nationwide Inpatient Sample 8-year period 1998 and 2005 Chest. Jun 2009 primary or secondary discharge diagnosis of PE hospital case-fatality rates length of hospital stay total hospital charges health care expenditures related to VTE and PE > $1.5 billion annually

57 yo male admitted for craniotomy for tumor On day of surgery filter placed for isolated peroneal vein thrombus by sonography D/C 2 days later on LMWH after successful tumor resection Returned to ED 1 day later with LLE seizure-like activity While in ED became acutely SOB, poor ABGs, coded and died

PIOPED (I) Evaluate nuclear scintigraphy for acute PE Low probability for PE Intermediate probability for PE 20-79% (35%) High probability for PE

Pulmonary Embolism Computed Tomography Direct visualization of thrombus

PIOPED II Evaluate multidetector CT for acute PE -CTV is high with a concordant clinical assessment, but additional testing is necessary when the clinical probability is inconsistent N Engl J Med June 2006

Patients do die from acute pulmonary Mechanism is still unknown in many It is probably right heart strain those are the ones that come to IR

45-year-old male recently diagnosed non-small-cell lung cancer and lower extremity DVT Presented to ED with pleuric chest pain and extreme SOB. On warfarin. 87% saturation despite 0 2.

increased pressures tamponade no mets The patient was started on heparin, but began to have increased symptoms

Right pre and post

Left pre and post

Pulmonary Embolism Thrombolytic Therapy Intravenous administration Intra-arterial administration

Contoversy exists for thrombolytic therapy at all is better than heparin for pulmonary embolism based -blind RCTs, with subgroup analysis of patients presenting with hemodynamically stable acute pulmonary embolism compared to those patients with a hemodynamic unstable condition, Cochrane Database Syst Rev. 2006

Pulmonary Embolism Thrombolytic Therapy Intravenous Administration Pre-thrombolysis Post-thrombolysis

Pulmonary Embolism Catheter Directed Thrombolytic Therapy One controlled trial of intravenous versus intra-arterial pharmacological thrombolysis using rtpa: Small patient numbers (n=34) 19 IA 15 IV No significant advantage to the intra-arterial route Verstraete et al. Circulation 1988; 77:353

Pulmonary Embolism Catheter Directed Thrombolytic Therapy Only case studies and small series mechanical devices No randomized controlled trials Early results are promising Mostly limited to patients with hemodynamic compromise contraindications to IV thrombolytics

Pulmonary Embolism Catheter Directed Thrombolytic Therapy Pharmacologic tpa reteplase Intraarterial Mechanical rotating pigtail catheter Angiojet Rheolytic System

Catheter fragmentation of acute PE 25 patients Hemodynamic impariment Rotating pigtail catheter + Fibrinolysis + Transcatheter thrombus aspiration Significantly decreased pulmonary artery pressures No mention of effect on survival Nakazawa et al. Br J Radiol. 2008; 81:848

Pulmonary Embolism Rheolytic thrombectomy 51 patients Single center Treated with AngioJet Technical success = 92.2% Significant improvement in obstruction, perfusion and Miller indexes (all P < 0.0001) -hospital Bradycardia Chechi et al. Catheter Cardiovasc Interv. 2009;73:506-13.

post pre Thrombolysis/Thrombectomy

Digonnet et al. Interact Cardiovasc Thorac Surg. 2007;6:27-9. Acute pulmonary embolism: a current surgical approach. March 1995 to December 2005, 21 patients underwent pulmonary embolectomy Group A Group B -massive PE/hemodynam stable w/ RV dysfunction

Why does one place an inferior vena cava filter? Prevent pulmonary embolism

John Hunter History IVC ligation prevent pelvic emboli circa 1940 Open IVC ligation mortality 14% venous stasis 33% Open IVC clipping/suturing mortality 12% venous stasis 33%

a slide showing cava clipping Caval ligation 1960s

Mobin-Uddin umbrella Edwards Laboratories IVC thrombosis rate 60% Introduced 1967

1 st reported percutaneous placement 1984 Greenfield filter 24 F Introducer 41% rate of CFV thrombosis AJR 1987; 149:1065-1066

more were placed smaller introducer Greenfield (Boston Scientific Corp) Stainless Steel 12 F, 24 F Titanium Titanium Greenfield Filter (1991) Over-the-Wire Stainless Steel Greenfield Filter (1995)

Permanent Inferior Vena Cava Filters 5 in United States Greenfield SS / Titanium Vena Tech Simon Nitinol TrapEase

IVC Filters Simon Nitinol (C.R. Bard) Nitinol Medical Technologies 1990

IVC Filters Vena Tech B Braun

Cook, Inc.

IVC Filters TrapEase (Cordis Endovascular) August 2000

Do they work? Do they hurt anybody?

A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis PREPIC Study Group 400 patients with proximal DVT randomly assigned vena caval filter (200 patients) no filter (200 patients) all pts were anticoagulated (unfract heparin 205, LMWH 195) N Engl J Med 1998; 338:409-416

PREPIC Study Group 12 days Symptomatic and non-symptomatic PE filter group 2 pts non-filter group 9 pts (1.1% vs 4.8%, p=0.03) N Engl J Med 1998; 338:409-416

Follow up Visits @ 3 mo, 1 yr Telephone 2 yrs 2 years DVT Filter group 37 pts Non-filter group 21 pts (20.8% vs 11.6% p=0.02) Mortality Filter group 43 pts Non-filter group 40 pts (21.6% vs 20.1%, p=ns)

Eight-Year Follow-Up of Patients With Permanent Vena Cava Filters in the Prevention of Pulmonary Embolism Original 400 pts follow up 396 patients (99%) 1X/year for 8 years by telephone Circulation 2005; 112:416-422

Symptomatic PE 9 patients in the filter group 24 patients in the no-filter group (p=0.008) DVT 57 patients in the filter group 41 patients in the no-filter group (p=0.042) Postthrombotic syndrome (70.3% vs 69.7%) Mortality 103 patients in the filter group 98 patients in the no-filter group (p=ns)

At 8 years, vena cava filters reduced the risk of pulmonary embolism but increased that of deep-vein thrombosis and had no effect on survival. Although their use may be beneficial in patients at high risk of pulmonary embolism, systematic use in the general population with venous thromboembolism is not recommended.

IVC filters: Cochrane analysis, 2009 11 studies, 1 randomized trial No firm conclusions regarding filter efficacy in the prevention of pulmonary embolism can be drawn from the PREPIC study. The group of people who received filters in the study varied significantly...notably those patients with DVT or PE and in whom anticoagulation has failed or cannot be administered. The PREPIC study used permanent filters.

The PREPIC study also lacked statistical power to detect a reduction in the incidence of pulmonary embolism over shorter and more clinically significant time periods. The failure of the PREPIC study to demonstrate a survival advantage was due to its older study population (mean age 73 years) with multiple other co-morbidities; only 7 deaths from PE The PREPIC study did show an increasing incidence of DVT that correlated to the length of time the filter was in situ.

Advantages of Retrievable Filters Offer all the benefits of permanent filters without the long-term venous thrombotic complications

Permanent versus Non-permanent Filters Optional filters retrievable convertible Temporary filters (tethered)

Retrievable Filters 5 in United States Günther-Tulip /Celect OptEase Recovery /G2 /G2 X ALN

Retrievable filters Never sure Works as well as permanent ones Cost greater

Cook Inc. Günther Tulip Celect

Günther Tulip Contraindications for removal thrombus >25% of cone pts high risk for PE Cook Inc.

Celect IVC filter Retrospective review of clinical data of 73 patients (22-89 years) August 2007 and June 2008 66% thrombus (legs/lungs/both) 34% prophylactic 3 pts symptoms of PE 2 (2.7%) diagnosed PE by imaging Follow-up abdominal CT 18 patients and demonstrated filter-related problems in 7 (10%/39%) (caval perforation/fracture) J Vasc Intervent Radiol Sept 2009

OptEase Cordis Endovascular

G2 Bard Peripheral Vascular G2 X

G2 Bard Peripheral Vascular

ALN optional filter ALN implants chirurgicaux Surgimed solutions

ALN optional filter

Angiotech F D A clearance June 2009

52-year-old gentleman who had an infected right total knee replacement Surgery included a right leg free fibular flap Chemically paralyzed postoperatively to promote graft success Triple lumen catheter inadvertently placed in the right carotid artery post-op

hemiparetic L side. craniectomy Postoperatively developed extensive DVT within the R upper extremity - non-occlusive thrombus RIJ - no thrombus LEs Started acutely on heparin Team requests superior vena cava filter

Indications for superior vena caval filtration Same as for IVC filtration? Contraindication to anticoagulation Progression of DVT or PE despite adequate anticoagulation Massive pulmonary clot burden Failure existing filter Prophylactic Questions? upper extemity DVT the same as lower? retrievable filters change anything? unknowns

Risks of upper extremity DVT? The natural history of UE thrombosis and risk of embolization are still matters of debate Pathophysiology of UE DVT is quite different from that of LE DVT UE disease may be more likely to be due to local, anatomic or mechanical factors than LE disease Spyropoulos AC. J Thromb Haemost. 2009; 7:1041-2

SVC filter placement Retrospective analysis Jan 1994-Aug 2005 TrapEase 38 (25%) Greenfield 116 (75%) 3 cases (1.9%) of pericardial tamponade Vascular 2009;17:44-50 1 misplacement into R brachiocephalic vein No known cases of symptomatic PE, caval occlusion, pneumothorax, or filter migration. Concluded: data reaffirmed the safety and effectiveness of SVC filter placement. Usoh et al. Ann Vasc Surg 2009; 23: 350-354

Does retrieval change the game?